Literature DB >> 7523993

Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra.

L Naudon1, I Leroux-Nicollet, J Costentin.   

Abstract

[3H]dihydrotetrabenazine ([3H]TBZOH) was used to label the monoamine vesicular transporter in the rat substantia nigra. An accumulation of neuronal vesicles in the substantia nigra pars compacta was observed after blockade of the fast axonal transport by a microinjection of colchicine (10 micrograms/2 microliters) into the medial forebrain bundle. This accumulation was measured after sustained 2-day pharmacological modifications of the central dopaminergic transmission. It was not modified after s.c. administration of either the direct dopamine (DA) receptor agonist bromocriptine (four injections of 4 or 6 mg/kg) or the DA receptor antagonist haloperidol (four injections of 0.5-1-1.5-2 mg/kg). Thus, it appears that these pharmacological modifications, imposed to the activity of the nigro-striatal dopaminergic system during 2 days, have no consequence on the rate of synthesis of its vesicles.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523993     DOI: 10.1016/0304-3940(94)90136-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization.

Authors:  David S Segal; Ronald Kuczenski; Meghan L O'Neil; William P Melega; Arthur K Cho
Journal:  Psychopharmacology (Berl)       Date:  2005-03-15       Impact factor: 4.530

2.  The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat.

Authors:  J M Wilson; S J Kish
Journal:  J Neurosci       Date:  1996-05-15       Impact factor: 6.167

3.  Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations.

Authors:  V Villemagne; J Yuan; D F Wong; R F Dannals; G Hatzidimitriou; W B Mathews; H T Ravert; J Musachio; U D McCann; G A Ricaurte
Journal:  J Neurosci       Date:  1998-01-01       Impact factor: 6.167

Review 4.  Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders.

Authors:  Nicolaas I Bohnen; Kirk A Frey
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.488

5.  In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations.

Authors:  Michael R Kilbourn; Elizabeth R Butch; Timothy Desmond; Phillip Sherman; Paul E Harris; Kirk A Frey
Journal:  Nucl Med Biol       Date:  2009-10-03       Impact factor: 2.408

6.  Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons.

Authors:  G A Ricaurte; U D McCann
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

7.  Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.

Authors:  F S Hall; K Itokawa; A Schmitt; R Moessner; I Sora; K P Lesch; G R Uhl
Journal:  Neuropharmacology       Date:  2013-08-24       Impact factor: 5.250

8.  Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs.

Authors:  Thea P Lillethorup; Andreas N Glud; Aage K O Alstrup; Ove Noer; Erik H T Nielsen; Anna C Schacht; Natalie Landeck; Deniz Kirik; Dariusz Orlowski; Jens Christian H Sørensen; Doris J Doudet; Anne M Landau
Journal:  Sci Rep       Date:  2018-10-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.